paliperidone + valproic acid

**paliperidone + valproic acid** is a non-branded combination of two pharmaceutical agents used concomitantly, most often in psychiatric practice for patients with disorders such as schizophrenia, bipolar disorder, or schizoaffective disorder. **Paliperidone** is an atypical antipsychotic acting primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors, thereby reducing psychotic and mood symptoms. **Valproic acid** is a broad-spectrum antiepileptic and mood stabilizer that increases brain levels of gamma-aminobutyric acid (GABA), contributing to its therapeutic effects in both epilepsy and bipolar disorder. Pharmacokinetic studies show that concomitant use of valproic acid (including as divalproex sodium) increases paliperidone's exposure (Cmax and AUC) by approximately 50%, though paliperidone does not significantly alter valproic acid levels. Both drugs have primary central nervous system effects and can increase certain adverse event risks when used together, most notably the potential for valproic acid-induced hyperammonemic encephalopathy, especially in combination with other antipsychotics[1][2][3][4][5].

Brand names

DepakoteInvega

Other names

paliperidone and valproic acid